Optimization of carboxylate-terminated poly(amidoamine) dendrimer-mediated cisplatin formulation

Drug Development and Industrial Pharmacy

Volumn 41, Issue 2, 2015, Pages 232-238

  Kulhari, Hitesh ^a   Pooja, Deep ^a   Singh, Mayank K ^a   Chauhan, Abhay S ^b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b Department of Pharmaceutical Sciences   (United States)

Author keywords

Cisplatin; Encapsulation; Formulation; Optimization; Poly(amidoamine) dendrimer

Indexed keywords

CARBOXYLIC ACID; CISPLATIN; DENDRIMER; ETHYLENEDIAMINE; PLATINUM; POLYAMIDOAMINE; ANTINEOPLASTIC AGENT; ETHYLENEDIAMINE DERIVATIVE; PAMAM STARBURST;

ARTICLE; DRUG FORMULATION; DRUG PURIFICATION; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; REPRODUCIBILITY; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; MEDICINAL CHEMISTRY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CISPLATIN; DENDRIMERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; ETHYLENEDIAMINES; HUMANS; IN VITRO TECHNIQUES;

EID: 84921917836     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.858735     Document Type: Article

References (28)

1. Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA 2003; 100:3611-16.
2. Gordon M, Hollander S. Review of platinum anticancer compounds. J Med 1993;24:209-65.
3. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59:9-17.
4. Gianasi E, Wasil M, Evagorou EG, et al. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur J Cancer 1999;35: 994-1002.
5. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev 1999;99:2451-66.
6. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
7. Nabuhiro N, Souichiro O, Horacio C, Miyamoto M. Novel cisplatinincorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 2003;63:8977-83.
8. Siddik ZH, Newell DR, Boxall FE, Harrap KR. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 1987;36:1925-32.
9. Stathopoulos GP. Liposomal cisplatin: a new cisplatin formulation. Anti-Cancer Drugs 2010;21:732-6.
10. Ohta S, Nitta N, Sonoda A, et al. Prolonged local persistence of cisplatin-loaded gelatin microspheres and their chemoembolic anticancer effect in rabbits. Eur J Radiol 2009;72: 534-40.
11. Fang JY, Hsu SH, Leu YL, Hu JW. Delivery of cisplatin from pluronic co-polymer systems: liposome inclusion and alginate coupling. J Biomater Sci Polym Ed 2009;20:1031-47.
12. Tomalia DA. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci 2005;30:294-324.
13. Tomalia DA, Fréchet JMJ, eds. Dendrimers and other dendritic polymers. Chichester: J Wiley & Sons Ltd; 2001.
14. Huang X, Wu Z, Gao W, et al. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin. Drug Dev Ind Pharm 2011;37: 419-27.
15. Chauhan AS, Jain NK, Diwan PV. Pre-clinical and behavioral toxicity profile of PAMAM dendrimer in mice. Proc R Soc A 2010;466:1535-50.
16. Chauhan AS, Diwan PV, Jain NK, Tomalia DA. Simple terminal functionalized poly(amidoamine) (PAMAM) dendrimers: in vivo active macromolecular anti-inflammatory agents. Biomacromolecule 2009;5:1195-202.
17. Chauhan AS, Svenson S, Reyna L, Tomalia DA. Solubility enhancement propensity of PAMAM nanoconstructs. Mater Matters Nanomater 2007;2:24-7.
18. Chauhan AS, Jain NK, Diwan PV. Solubility enhancement of indomethacin using dendrimer complex and bio-disposition profile of these complexes in arthritic rats. J Drug Targeting 2004;12: 575-83.
19. Chauhan AS, Sridevi S, Chalasani KB, et al. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J Control Release 2003;90:335-43.
20. Svenson S, Chauhan AS. Dendrimers for enhanced drug solubilization. Nanomedicine 2008;3:679-702.
21. Kulhari H, Deep Pooja, Prajapati SK, Chauhan AS. Performance evaluation of PAMAM dendrimer based Simvastatin formulations. Int J Pharm 2011;405:203-9.
22. Asthana A, Chauhan AS, Diwan PV, Jain NK. Poly (amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS Pharm Sci Tech 2005;6:E536-42.
23. Kulhari H, Kulhari DP, Prajapati SK, Chauhan AS. Pharmacokinetic and pharmacodynamic studies of poly(amido)amine dendrimer based simvastatin oral formulations for the treatment of hypercholesterolemia. Mol Pharm 2013;10:2528-33.
24. Kirkpatrick GJ, Plumb JA, Sutcliffe OB, et al. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 2011;105:1115-22.
25. Yellepeddi VK, Kumar A, Maher DM, et al. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 2011;31:897-906.
26. Haririan I, Alavidjeh SM, Khorrramizadeh MR, et al. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity in vitro against different cancer cell lines. Int J Nanomed 2010;5:63-75.
27. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999;10: 767-76.
28. Yotsuyanagi T, Usami M, Noda Y, Nagata M. Computational consideration of cisplatin hydrolysis and acid dissociation in aqueous media: effect of total drug concentrations. Int J Pharm 2002;246:95-104.